Imipenem versus moxalactam in the treatment of serious infections.

AUTOR(ES)

Eron, L J

RESUMO

Imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) was compared to moxalactam in a randomized therapeutic trial involving 39 evaluable patients with serious bacterial infections. Of those treated with imipenem, 89% were cured or improved versus 60% for moxalactam (P = 0.06). Although mucocutaneous fungal infections occurred in both groups (25 and 10%, respectively), Streptococcus faecalis superinfection was seen in two patients in the moxalactam group only. Adverse drug reactions occurred with both drugs, although bleeding occurred in three patients treated with moxalactam.

Documentos Relacionados

• Moxalactam in the therapy of serious infections.
• Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
• Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
• Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections.
• Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.